



CONMED provides safe, high-quality allograft tissues and biologics from MTF Biologics to meet the needs of physicians and their patients.

Partnership

CONMED and MTF Biologics have entered into a long-term partnership through a series of distribution and development agreements, making CONMED the exclusive, worldwide promoter of MTF Sports and Extremity related allograft tissues.

Through our partnership with MTF Biologics, CONMED provides a wide variety of allograft tissues and biologic solutions that address a range of orthopedic procedures. Our portfolio of solutions includes soft tissue allografts with and without bone blocks for primary or revision reconstructive surgeries, osteochondral allografts and instrumentation for cartilage repair, meniscal allografts for subtotal or total meniscectomy, glenoid resurfacing, and interpositional arthroplasty. Allopatch HD® acellular human dermis is available for use as an augmentation scaffold and wound covering. The ENHANCE™ Amniotic Membrane is an amnion/chorion based allograft which may be used as a protective barrier for surgical and non-surgical applications. Lastly, CONMED offers a full line of pre-shaped and pre-sized allograft segments from cortical and cancellous bone to address deformity corrections and reconstructive extremity procedures.







About MTF Biologics

MTF Biologics is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery, and care for recipients, donors, and their families. Since its inception, MTF Biologics has recovered over 139,000 donors and distributed over 9 million grafts¹ while maintaining an exemplary safety record. Due to the safety steps instituted by the Board of Directors, Medical Board of Trustees, and Donation Board of Trustees, MTF Biologics has become a leading tissue bank in the United States and is one of the largest providers of allografts in the world.

Highlights

- MTF leads the industry in donor selection criteria and the standards exceed those set by the American Association of Tissue Banks (AATB) and most other tissue banks
- MTF defers more donors than any other tissue bank for the following reasons: cancer, illegal drug use, infection, high-risk behavior, age, osteoporosis, steroids, and end stage renal disease/chronic dialysis
- MTF never accepts deferred donors from other tissue banks
- MTF employs Nucleic Acid Testing and conducts serological tests on all donors
- MTF is the only tissue bank in the industry to use the VanGuard Method™, a qualitative and quantitative data assessment tool designed to evaluate the incoming bioburden levels of donor tissue
- · MTF believes in minimal processing to preserve the biomechanical integrity and biochemistry of every graft
- MTF is the industry leader in providing "aseptic" tissue and is referenced in multiple clinical studies that have similar results to autograft in the aging athlete as well as the young active population of patients²⁻⁵

Processed by:
MTF Biologics
125 May Street, Edison, New Jersey 08837
Phone: 732-661-0202 Fax: 732-661-2298
Website: www.mtfbiologics.org

MTF tissue forms and products are protected by one or more issued or licensed United States patents.

A list of patents on available tissues and related technologies may be found on the MTF website

http://www.mtfbiologics.org/patents. The CONMED Linvatec logo, CONMED and CONMED Linvatec are

trademarks or registered trademarks of CONMED Corporation or its subsidiaries. ALLOPATCH HD®,

ENHANCE™, VanGuard Method™ and MTF Biologics are trademarks or registered trademarks of MTF Biologics.

¹ https://www.mtfbiologics.org/who-we-serve/donors-community/recipients 2 Greenberg DD, Robertson M, et al. J. Bone Joint Surg. Am. 2010; Vol. 92; No. 14, 2402-2408.

³ Poehling GG, Curl WW, et al. Arthroscopy 2005; Vol. 21; No. 7, 774-785. ⁴ Barber AF, Aziz-Jacob J, et al. Arthroscopy 2010; Vol. 26; No. 4, 488-493.

 $^{^{5}\,\}mathrm{Shah}$ AA, McCulloch PC, et al. Arthroscopy 2010; Vol. 26; No. 5, 667-674.